Work

The National Institute of Allergy and Infectious Diseases Decision to Stop the Adaptive COVID-19 Trial

Year: 2020

Type: editorial

Abstract: O n April 29, the National Institute of Health disclosed the preliminary findings of the ACTT-1 (Adaptive COVID-19 Treatment Trial) (NCT04280705), the first clinical trial in the United States to evaluate an experimental treatment for coronavirus disease-2019 (COVID-19).ACTT was designed as an adaptive, randomized, double-blind, placebo-controlled trial to evaluate the safety and ef-

Source: JACC Basic to Translational Science

DOI: 10.1016/j.jacbts.2020.05.002

Authors: Jessica Mozersky, Douglas L. Mann, James M. DuBois

Institution: Washington University in St. Louis

Language: English

Topic: COVID-19 Clinical Research Studies

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,400

OpenAlex ID: W3035968149

Cites: 10

Cited by: 12

Related to: 10